Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.72 |
| ▸ | NPC1 | O15118 | 9/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 8/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.71 |
| ▸ | LMNA | P02545 | 7/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | PLEC | Q15149 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474662 | 0.89 | RAB9A (0.67) | RAB9ANPC1NPSR1MEN1KMT2A | |
| SCHEMBL9911645 | 0.87 | RAB9A (0.77) | RAB9ANPC1NPSR1MEN1KMT2A | |
| SCHEMBL4284349 | 0.86 | RAB9A (0.78) | RAB9ANPC1NPSR1MEN1KMT2A | |
| SCHEMBL20507264 | 0.86 | RAB9A (0.72) | RAB9ANPC1NPSR1MEN1KMT2A | |
| SCHEMBL12751395 | 0.86 | RAB9A (0.66) | RAB9ANPC1NPSR1MEN1KMT2A | |
| SCHEMBL1474410 | 0.85 | RAB9A (0.67) | RAB9ANPC1NPSR1MEN1KMT2A | |
| SCHEMBL9911628 | 0.85 | RAB9A (0.73) | RAB9ANPC1NPSR1MEN1KMT2A | |
| SCHEMBL4281968 | 0.85 | RAB9A (0.77) | RAB9ANPC1NPSR1MEN1KMT2A | |
| SCHEMBL15190454 | 0.84 | RAB9A (0.54) | RAB9ANPC1NPSR1MEN1KMT2A | |
| SCHEMBL1474970 | 0.84 | RAB9A (0.64) | RAB9ANPC1NPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404304-B1 | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | SIERRA SCIENCES, LLC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250179122-A1 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | SIERRA SCIENCES, LLC | 2025-06-05 | — | — | US | disclosed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-20090143451-A1 | COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME | SIERRA SCIENCES INC. | 2009-06-04 | — | — | US | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179122-A1 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | TERT, RNGTT, TERF2 | RAB9A 4044/4885NPC1 2894/4885NPSR1 4839/4885 |
| US-12404304-B1 | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | TERT, TELO2, POT1 | RAB9A 4662/4885NPC1 4442/4885NPSR1 4860/4885 |
| US-20090143451-A1 | COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME | TERT, TERF2, RNMT | RAB9A 3970/4885NPC1 2996/4885NPSR1 4818/4885 |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | RAB9A 2013/4885NPC1 2242/4885NPSR1 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.